Aslan's latest cancer focus also flops, leaving just two major programs for the troubled biotech

Aslan $ASLN has stumbled back into the failure pit.

When their lead drug failed to treat gastric cancer, Aslan Pharmaceuticals announced they were going to focus on another type: biliary tract cancer (BTC). When the gastric failure forced them to cut 30% of their staff, they again emphasized the new target as one of three remaining programs.